Zonisamide

Overview of the use of Zonisamide in medical treatment

Engineered Monoclonal Antibodies

Diagram of engineered monoclonal antibodies

Engineered monoclonal antibodies are a class of biological therapies that are designed to target specific antigens on the surface of cells. These antibodies are produced using recombinant DNA technologies and are used in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases.

Structure and Function

Monoclonal antibodies are composed of two identical heavy chains and two identical light chains, forming a Y-shaped molecule. The tips of the "Y" contain the antigen-binding sites, which are highly specific to the target antigen. This specificity allows monoclonal antibodies to bind to their target with high affinity, blocking or modulating the function of the antigen.

Types of Engineered Monoclonal Antibodies

There are several types of engineered monoclonal antibodies, each designed for specific therapeutic purposes:

• Chimeric antibodies: These antibodies are composed of murine (mouse) variable regions and human constant regions. They are less immunogenic than fully murine antibodies.

• Humanized antibodies: These antibodies are mostly human, with only the antigen-binding sites derived from murine sources. This reduces the risk of immune reactions.

• Fully human antibodies: These are entirely human in origin, produced using transgenic mice or phage display technologies.

• Bispecific antibodies: These antibodies are engineered to bind two different antigens simultaneously, offering unique therapeutic mechanisms.

Applications in Medicine

Engineered monoclonal antibodies have revolutionized the treatment of many diseases:

• Cancer therapy: Monoclonal antibodies can target specific tumor antigens, leading to direct tumor cell killing or recruitment of immune cells to attack the tumor.

• Autoimmune diseases: By targeting specific components of the immune system, monoclonal antibodies can reduce inflammation and tissue damage in diseases such as rheumatoid arthritis and multiple sclerosis.

• Infectious diseases: Monoclonal antibodies can neutralize pathogens or their toxins, providing passive immunity or enhancing the host's immune response.

Production

The production of engineered monoclonal antibodies involves several steps:

1. Antigen identification: The target antigen is identified and characterized. 2. Hybridoma technology: B cells from immunized animals are fused with myeloma cells to create hybridomas that produce the desired antibody. 3. Recombinant DNA technology: Genes encoding the antibody are cloned and expressed in suitable host cells, such as Chinese hamster ovary cells. 4. Purification and formulation: The antibodies are purified and formulated for clinical use.

Challenges and Future Directions

While engineered monoclonal antibodies have shown great promise, there are challenges such as high production costs, potential for immune reactions, and the development of resistance. Ongoing research aims to improve antibody design, reduce immunogenicity, and enhance therapeutic efficacy.

Related Pages

• Monoclonal antibody therapy
• Biopharmaceutical
• Immunotherapy
• Hybridoma technology

Zonisamide is a medication primarily used as an adjunctive therapy in the treatment of epilepsy. It is classified as a sulfonamide and is known for its anticonvulsant properties. Zonisamide is effective in managing partial seizures and is sometimes used off-label for other neurological conditions.

Pharmacology

Zonisamide works by stabilizing neuronal membranes and suppressing neuronal hypersynchronization through the inhibition of voltage-sensitive sodium and calcium channels. It also modulates the release of neurotransmitters, which contributes to its anticonvulsant effects.

Indications

Zonisamide is indicated for the treatment of partial seizures in adults with epilepsy. It is often used in combination with other antiepileptic drugs (AEDs) when monotherapy is insufficient.

Dosage and Administration

The dosage of zonisamide is typically individualized based on the patient's response and tolerance. It is usually started at a low dose and gradually increased. The medication is available in capsule form and is taken orally.

Side Effects

Common side effects of zonisamide include dizziness, drowsiness, headache, nausea, and loss of appetite. Serious side effects can include metabolic acidosis, kidney stones, and severe skin reactions. Patients should be monitored for signs of depression or suicidal thoughts.

Contraindications

Zonisamide is contraindicated in patients with a known hypersensitivity to sulfonamides. Caution is advised in patients with renal impairment or a history of kidney stones.

Mechanism of Action

Zonisamide's mechanism of action involves the blockade of sodium and calcium channels, which reduces the repetitive firing of neurons. It also has a weak inhibitory effect on carbonic anhydrase, which may contribute to its efficacy in seizure control.

Research and Development

Ongoing research is exploring the potential use of zonisamide in other neurological disorders, such as Parkinson's disease and migraine prophylaxis. Its neuroprotective properties are also being investigated.

Also see

• Epilepsy
• Anticonvulsant
• Sodium channel blocker
• Calcium channel blocker

References

• 

  Zonisamide

• 

  Zonisamide